Fearful of losing all of his central vision to the gradual blinding effects of Age-Related Macular Degeneration (AMD), a California-based researcher with a long track record of commercialized ocular and eye health innovations embarked on a journey to find a solution. After studying the cause and effects of AMD, he began self-experimenting with a new pharmaceutical formula in an attempt to save his central vision.
Following several years of testing and reformulation, his oral treatment, AMD Stopper, has demonstrated an ability to slow and even halt the progression of AMD's vision-stealing effects. The inventor and his ophthalmologist, a retinal specialist, confirm that he has recovered 75% of his central vision in the previously damaged eye. Such vision recovery is unprecedented and marks a significant breakthrough in the treatment of AMD.
“The originator of the AMD Stopper formulation and his ophthalmologist, a retina surgeon, confirmed that he has not only stopped the progression of the disease but recovered a significant portion of the vision in the affected eye,” commented James Kraushaar, President of AMD STOPPER. “Vision recovery with AMD is an unprecedented achievement and marks a significant breakthrough in eye health.”
Age-Related Macular Degeneration is a significant global health issue, with an estimated 18.34 million Americans exhibiting early AMD and 1.49 million suffering from the vision threatening advanced (late) form of AMD which includes geographic atrophy, a condition which leads to irreversible loss of vision over time.
Globally, AMD is a leading cause of vision loss in adults over the age of 50. (Source: ‘Prevalence of Age-Related Macular Degeneration in the US in 2019’, JAMA Ophthalmol, Nov. 2022). The introduction of AMD Stopper offers new hope for those affected by this debilitating condition.
The most common symptoms of age-related macular degeneration include:
- Blurry or fuzzy vision
- Difficulty recognizing familiar faces
- Straight lines appear wavy
- A dark, empty area or blind spot in the center of vision
- Loss of central vision, which is necessary for driving, reading, recognizing faces and performing close-up work
To bring AMD Stopper to market, AMD Stopper is seeking to partner with pharmaceutical manufacturers in Mexico, Latin America, Europe, and North America to prepare and achieve marketing approval. Of particular interest is entering the Mexican market where an estimated 15 million are suffering from the blinding effects of AMD.
For more information about AMD Stopper and how you can support its development and approval, send email inquiries to: [email protected]
About AMD STOPPER Inc.
AMD Stopper Inc. is a newly organized company which holds the formulas, patent applications, and intellectual property rights to the formula developed by an eye care researcher to treat Age-Related Macular Degeneration.
AMD Stopper is the sole owner and licensee of this groundbreaking oral medication and will either be manufactured by the Company or licensed to an FDA-certified drug manufacture under the supervision of the scientists, Ophthalmologists, and physicians employed or under contract.